Deutsche Märkte geschlossen

uniQure N.V. (QURE)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
5,28-0,13 (-2,50%)
Ab 01:19PM EDT. Markt geöffnet.

uniQure N.V.

Paasheuvelweg 25
Amsterdam 1105 BP
Netherlands
31 20 240 6000
https://www.uniqure.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter480

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Matthew Craig KapustaCEO & Executive Director1,16MN/A1972
Mr. Christian KlemtCFO, Principal Financial Officer & GM of Amsterdam Site566,36kN/A1973
Mr. Pierre CalozChief Operating Officer951,1kN/A1972
Prof. Hugo KatusChairman of Scientific Advisory Board and Managing Director of UniQure-GermanyN/AN/AN/A
Mr. Richard Porter Ph.D.Chief Business & Scientific OfficerN/AN/AN/A
Dr. Jeannette Potts J.D., Ph.D.Chief Legal & Compliance OfficerN/AN/A1962
Dr. Tamara Tugal Ph.D., MBABusiness Development DirectorN/AN/AN/A
Ms. Carla PoulsonInterim Chief People and Culture OfficerN/AN/AN/A
Ms. Maria E. CantorChief Corporate Affairs Officer491,12kN/A1968
Dr. Amin Abujoub Ph.D.Chief Quality OfficerN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Corporate Governance

uniQure N.V.s ISS Governance QualityScore, Stand 1. März 2024, lautet 2. Die grundlegenden Scores sind Audit: 5, Vorstand: 3, Shareholderrechte: 1, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.